Los Angeles Capital Management LLC Decreases Stake in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Los Angeles Capital Management LLC lowered its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 1.9% in the fourth quarter, Holdings Channel reports. The firm owned 324,011 shares of the company’s stock after selling 6,280 shares during the period. Los Angeles Capital Management LLC’s holdings in Organogenesis were worth $1,037,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Captrust Financial Advisors bought a new stake in shares of Organogenesis in the 3rd quarter valued at approximately $36,000. Intech Investment Management LLC acquired a new position in Organogenesis during the third quarter worth about $43,000. Pallas Capital Advisors LLC boosted its position in shares of Organogenesis by 70.8% in the 3rd quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock valued at $63,000 after purchasing an additional 9,048 shares during the period. Palumbo Wealth Management LLC acquired a new position in shares of Organogenesis in the 4th quarter valued at $65,000. Finally, Metis Global Partners LLC purchased a new position in shares of Organogenesis during the third quarter valued at $84,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis Stock Performance

Shares of NASDAQ ORGO opened at $6.22 on Friday. Organogenesis Holdings Inc. has a one year low of $2.16 and a one year high of $6.40. The business’s 50-day moving average price is $3.42 and its two-hundred day moving average price is $3.25. The company has a market capitalization of $782.27 million, a P/E ratio of -103.70 and a beta of 1.77. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74.

Insider Buying and Selling at Organogenesis

In other news, CEO Gary S. Gillheeney sold 55,615 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the sale, the chief executive officer now directly owns 3,044,779 shares in the company, valued at approximately $10,230,457.44. This represents a 1.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold a total of 278,116 shares of company stock valued at $991,190 in the last quarter. Corporate insiders own 36.90% of the company’s stock.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.